Swiss National Bank grew its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 1.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 147,300 shares of the company’s stock after acquiring an additional 1,900 shares during the period. Swiss National Bank owned about 166,459.49% of Neurocrine Biosciences worth $9,027,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in NBIX. World Asset Management Inc bought a new position in shares of Neurocrine Biosciences during the third quarter worth about $246,000. Asymmetry Capital Management L.P. lifted its position in shares of Neurocrine Biosciences by 51.3% during the third quarter. Asymmetry Capital Management L.P. now owns 51,497 shares of the company’s stock worth $3,156,000 after purchasing an additional 17,467 shares during the last quarter. Birchview Capital LP lifted its position in shares of Neurocrine Biosciences by 107.9% during the third quarter. Birchview Capital LP now owns 52,400 shares of the company’s stock worth $3,211,000 after purchasing an additional 27,200 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Neurocrine Biosciences by 7.2% during the third quarter. American Century Companies Inc. now owns 36,148 shares of the company’s stock worth $2,215,000 after purchasing an additional 2,443 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System lifted its position in shares of Neurocrine Biosciences by 0.7% during the third quarter. State Board of Administration of Florida Retirement System now owns 120,426 shares of the company’s stock worth $7,380,000 after purchasing an additional 810 shares during the last quarter.

Several equities analysts have recently commented on NBIX shares. Robert W. Baird reaffirmed an “outperform” rating and set a $66.00 price target on shares of Neurocrine Biosciences in a research report on Thursday, September 21st. Jefferies Group LLC reaffirmed a “buy” rating and set a $69.00 price target (up previously from $66.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 3rd. Leerink Swann reaffirmed an “outperform” rating and set a $83.00 price target (up previously from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Cowen and Company reaffirmed an “outperform” rating and set a $65.00 price target (up previously from $60.00) on shares of Neurocrine Biosciences in a research report on Wednesday, August 9th. Finally, Barclays PLC increased their price target on shares of Neurocrine Biosciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a research report on Thursday, November 2nd. One investment analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $78.88.

In related news, insider Christopher Flint Obrien sold 52,817 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $57.50, for a total transaction of $3,036,977.50. Following the transaction, the insider now owns 101,790 shares in the company, valued at $5,852,925. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kyle Gano sold 24,818 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $71.05, for a total transaction of $1,763,318.90. Following the transaction, the insider now owns 84,596 shares in the company, valued at approximately $6,010,545.80. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 150,710 shares of company stock worth $9,758,593. Corporate insiders own 4.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Neurocrine Biosciences, Inc. (NBIX) Stake Increased by Swiss National Bank” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/21/neurocrine-biosciences-inc-nbix-stake-increased-by-swiss-national-bank.html.

Shares of Neurocrine Biosciences, Inc. (NASDAQ NBIX) opened at $71.77 on Tuesday. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences, Inc. has a twelve month low of $37.35 and a twelve month high of $75.98.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Wednesday, November 1st. The company reported ($0.13) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.36. The business had revenue of $60.77 million for the quarter, compared to the consensus estimate of $29.38 million. During the same period last year, the firm posted ($0.43) EPS. equities analysts anticipate that Neurocrine Biosciences, Inc. will post -1.74 earnings per share for the current year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.